Diphtheria Completed Phase 4 Trials for Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (DB10991)

Also known as: Corynebacterium diphtheriae infection / Infection due to Corynebacterium diphtheriae (disorder) / Diphtheria caused by Corynebacterium diphtheriae (disorder) / Diphtheria, unspecified

DBCOND0000394 (Diphtheria)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01711645Tdap Vaccine in Post-Partum WomenPrevention
NCT01629589Immunogenicity of Adacel® and BOOSTRIX® Vaccines in AdolescentsPrevention
NCT01491087Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in ChinaPrevention
NCT01457547Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination CoursePrevention
NCT01439165Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous DosePrevention
NCT01437423Regulatory Post-Marketing Surveillance Study for TETRAXIM™Prevention
NCT01362322Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old AdolescentsPrevention
NCT01311557Study of Adacel® Vaccine Administered to Persons 10 Years of AgePrevention
NCT01294605Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)Prevention
NCT01147900Evaluation of Boostrix™10 Years After Previous Booster VaccinationPrevention
NCT01137435Post Marketing Surveillance for ADACEL™ in South KoreaPrevention
NCT01031303Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of AgePrevention
NCT00777257Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap VaccinePrevention
NCT00753649Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in InfantsPrevention
NCT00712959Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous DosePrevention
NCT00635128Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio VaccinePrevention
NCT00611559Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old ChildrenPrevention
NCT00610168Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.Prevention
NCT00548171Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058Prevention
NCT00457249A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and OlderPrevention
NCT00347958Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® VaccinePrevention
NCT00319553Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®Prevention
NCT00282295US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal DiseasePrevention
NCT00255021Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in ThailandPrevention
NCT00254917Assessment of the Immunogenicity and Safety of PENTAXIM™ in PhilippinesPrevention